BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-7782 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-7782\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07123129-11115@assetmemo.bio
DTSTAMP:20261121T004552Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-7782: Phase 1 readout est. (NCT07123129)
DESCRIPTION:SHR-7782\, phase 1.\nStudy: A Trial of SHR-7782 for Treatment o
 f Advanced Malignant Tumors\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/shr-7782#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07123129
URL:https://assetmemo.bio/drug/shr-7782#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
